Kymera Therapeutics, Inc. $KYMR Holdings Trimmed by Atika Capital Management LLC

Atika Capital Management LLC reduced its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 44.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,300 shares of the company’s stock after selling 65,300 shares during the period. Atika Capital Management LLC owned approximately 0.11% of Kymera Therapeutics worth $4,602,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. BVF Inc. IL lifted its position in shares of Kymera Therapeutics by 6.6% during the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock valued at $240,138,000 after acquiring an additional 340,909 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Kymera Therapeutics by 5.2% during the second quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock valued at $52,075,000 after purchasing an additional 59,347 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after purchasing an additional 491,737 shares during the last quarter. Commodore Capital LP acquired a new position in shares of Kymera Therapeutics in the 2nd quarter valued at $32,730,000. Finally, Dimensional Fund Advisors LP increased its stake in Kymera Therapeutics by 29.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 731,420 shares of the company’s stock worth $41,409,000 after purchasing an additional 168,055 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have commented on the stock. Oppenheimer upped their price objective on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Citigroup lifted their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Leerink Partners upped their price target on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. Finally, Piper Sandler lifted their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $119.50.

Insider Transactions at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total value of $2,707,800.00. Following the transaction, the chief executive officer owned 666,195 shares of the company’s stock, valued at $60,130,760.70. This trade represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Bruce N. Jacobs sold 4,895 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $85.30, for a total transaction of $417,543.50. Following the completion of the sale, the chief financial officer owned 232,588 shares of the company’s stock, valued at $19,839,756.40. The trade was a 2.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 197,239 shares of company stock worth $17,159,153. 16.01% of the stock is currently owned by company insiders.

Kymera Therapeutics Trading Down 3.6%

Shares of NASDAQ:KYMR opened at $81.52 on Thursday. The stock has a market capitalization of $6.66 billion, a PE ratio of -22.15 and a beta of 2.20. Kymera Therapeutics, Inc. has a 1 year low of $19.44 and a 1 year high of $103.00. The firm has a fifty day moving average price of $79.09 and a 200 day moving average price of $67.82.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The company had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.Kymera Therapeutics’s quarterly revenue was down 60.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.88) EPS. On average, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.